The Role of Adipocyte Mediators, Inflammatory Markers and Vitamin D in Gestational Diabetes by Sedigheh Soheilykhah
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
The Role of Adipocyte Mediators,  
Inflammatory Markers and Vitamin D  
in Gestational Diabetes  
Sedigheh Soheilykhah 
Shahid Sadoughi University of Medical Sciences 
Iran 
1. Introduction 
Gestational diabetes mellitus (GDM) usually reveals itself in the latter half of pregnancy and 
it is identified by carbohydrate intolerance of variable severity. 
The presence of GDM has implications for both the mother and the baby. Perinatal 
morbidity includes macrosomia, hypoglycemia, hyperbilirubinaemia and respiratory 
distress syndrome which lead to the subsequent complications (Hod et al., 1991). Long term 
outcomes for the offspring may include obesity and diabetes independent of genetic factors 
(Silverman et al., 1995; Van Assche et al., 1992, 2001). For the mother there is an increased 
risk of overt type 2 diabetes later in life (Mestman, 1987; O'Sullivan, 1989). Both type 2 
diabetes and gestational diabetes have common pathogenic mechanisms where pregnancy 
tends to expose disease in those women who are at risk of developing type 2 diabetes later 
in life. Similar to all forms of hyperglycemia, GDM is characterized by insulin levels that are 
inadequate to proper insulin requirement (Metzger et al.,2007).The pathogenesis of GDM 
has not been clearly defined. The most common hypothesis is that GDM is caused by 
decreasing insulin sensitivity and increasing anti-insulin hormones that are secreted by the 
placenta during pregnancy, such as human placental  lactogen, prolactin, glucocorticoid and 
progesterone (Xue-lian et al., 2008). 
It has become increasingly evident that endocrine/metabolic hormones such as leptin, 
adiponectin, resistin, proinflammatory mediators including C-reactive protein ( CRP) are 
strongly linked with abnormal carbohydrate metabolism. 
In recent times a number of first trimester studies have shown association of different 
biomarkers with the development of GDM. These include elevated serum or plasma C-
reactive protein (Wolf et al., 2003), lower sex hormone-binding globulin (Thadhani et al., 
2003), increased placental growth factor (Ong et al., 2004) and elevated leptin (Qiu et al., 
2004) and decreasing of adiponectin concentration. 
Some studies have recommended that Vitamin D deficiency could play a role in 
pathogenesis of gestational diabetes. 
This chapter will focus on the studies about the role of adipocytes mediators, 
proinflammatory factors and vitamin D in gestational diabetes. 
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2. Adipocyte mediators 
It is becoming obvious that adipose tissue is not just a storage for extra energy but that it 
secretes a number of biologically active peptides as a group named adipocytokines that 
control glucose and fatty acid metabolism (Youn et al.,2004). These peptides have similar  
properties with cytokines, and so referred to as "adipocytokines“,  e.g. leptin, tumor necrosis 
factor-ǂ(TNF-ǂ), interleukin 6 (IL-6), adiponectin  and  resistin. These adipocytokines may 
influence activity of other tissues (Nedvidkova et al., 2005). 
2.1 Adiponectin 
2.1.1 Adiponectin structure  
Adiponectin is a 244-amino-acid-long polypeptide that regulates a number of metabolic 
processes, including glucose regulation and fatty acid catabolism. Adiponectin is exclusively 
secreted from adipose tissue into the circulation and is very plentiful in plasma relative to 
other hormones. Adiponectin concentrations ranging from 5 to 30mg/ml and  accounting 
for approximately 0.01% of total plasma protein . Females have higher levels of plasma 
concentration than males (Díez & Iglesias, 2003). 
Adiponectin was first identified in mice as a transcript overexpressed in preadipocytes 
(Lara-Castro et al.,  2007) differentiating into adipocyte (Matsuzawa et al., 2004). The human 
homologue was recognized as the most abundant transcript in adipose tissue. As opposed 
to anticipation, in spite of being produced in a fat tissue, adiponectin was found to decline 
in obesity (Díez & Iglesias, 2003; Nedvídková et al., 2005; Ukkola & Santaniemi, 2002). This 
down regulation has not been clearly described. The gene was localised to chromosome 
3p27, a region highlighted as affecting genetic vulnerability to obesity and type 2 diabetes. 
Supplementation by varying forms of adiponectin improved control of insulin, blood 
glucose and triglyceride levels in mouse models. 
Berbelin, a herbal folk medicine, has been shown to increase adiponectin expression which 
partly explains its advantageous effects on metabolic disturbances (Choi et al., 2009). 
A reduction in adiponectin expression is associated with insulin resistance in animal 
models. Administration of adiponectin has been accompanied by a reduction in plasma 
glucose and an increase in insulin sensitivity. In addition, thiazolidinediones, drugs that 
increase insulin sensitivity by stimulation of the peroxisome proliferator-activated receptor-
δ, increase plasma adiponectin and mRNA levels in mice. 
A recent study has shown that phosphorylation and Levels of the hormone are conversely 
correlated with body fat proportion in adults although the association in infants and young 
children is less clear. The hormone plays a role in the inhibition of the metabolic disturbance 
that may end in type 2 diabetes (Ukkola & Santaniemi, 2002), obesity, atherosclerosis (Díez 
& Iglesias, 2003), non-alcoholic fatty liver diseases (NAFLD) and independent risk factors 
for metabolic syndrome (Renaldi et al., 2009)., Levels of adiponectin are decreased in 
diabetics compared to non-diabetics. Weight loss significantly increases circulating levels 
(Coppola et al., 2009).  
Adiponectin automatically self-associates into larger structures. Initially, three adiponectin 
molecules bind together to form a homotrimer. The trimers continue to self-associate and 
form hexamers or dodecamers. Like the plasma concentration, the relative levels of the 
higher-order structures are sexually dimorphic, where females have increased proportions 
of the high-molecular weight forms. 
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Adiponectin exerts some of its weight reduction effects via the brain. This is similar to the 
action of leptin, but the two hormones perform complementary actions, and can have 
additive effects (Nedvídková et al., 2005). 
2.1.2 Metabolic effect of adiponectin 
Adiponectin affects glucose flux through decreasing gluconeogenesis and increasing glucose 
uptake (Díez & Iglesias, 2003; Nedvídková et al., 2005; Vasseur et al., 2003). Adiponectin has 
a role in lipid catabolism (Vasseur et al., 2003) by ǃ-oxidation and triglyceride clearance 
(Nedvídková et al., 2005). The other metabolic effects of adiponectin are protection against 
endothelial dysfunction and improvement of insulin sensitivity and weight loss, and control 
of energy metabolism (Vasseur et al., 2006).Adiponectin has also another effects, including 
putative insulin-sensitising, anti-atherogenic and anti inflammatory characteristics (Berg et 
al., 2002; Ukkola & Santaniemi, 2002).  
Consistent with the low circulating levels of adiponectin observed in type 2 diabetes, 
adiponectin concentration is contrarily related to both insulin resistance and central 
adiposity (Arita et al., 1999; Weyer et al., 2001). Low baseline adiponectin concentration can 
predict the subsequent development of insulin resistance although elevated baseline levels 
have been shown to be protective against the succeeding development of type 2 diabetes 
(Daimon et al., 2003; Lindsay et al., 2002; Snehalatha et al., 2003; Spranger et al. , 2003). 
Recognition of gestational diabetes mellitus helps in identification of populations of young 
women at high risk of developing type 2 diabetes. Therefore, reduction in serum 
adiponectin levels in GDM may be comparable to type 2 diabetes.  
2.1.3 Adiponectin and GDM 
Some studies exhibited hypoadiponectinemia in pregnant women with gestational diabetes. 
A cross sectional study of 180 women in their third trimesters illustrated gestational diabetic 
women had more hypoadiponectinemia compared with normoglycemic controls after 
adjustment for covariates including insulin resistance. This study showed adiponectin 
concentration is an independent correlate of beta cell function in late pregnancy. 
Adiponectin was correlated with insulin secretion-sensitivity index (ISSI). ISSI was 
positively correlated with adiponectin and negatively correlated with GDM and IGT. 
Therefore, adiponectin may play a principal role in mediating insulin resistance and beta 
cell malfunction in the development of diabetes (Rentakaran et al., 2005).To determine 
whether adiponectin relate to the postpartum metabolic disturbance linking GDM with type 
2 diabetes a cohort study was done on 487 pregnant wemen in pregnancy and at 3 months 
post partum. This study demonstrated adiponectin was related to postpartum insulin 
sensitivity and  hypoadiponectinemia in pregnancy predicts postpartum insulin resistance, 
beta cell dysfunction and fasting glycaemia, and hence may be relevant to the 
pathophysiology relating GDM with type 2 diabetes (Rentakaran et al., 2010). To investigate 
level of adiponectin and metabolic factors in women with gestational diabetes a cross 
sectional study was done . The result of this study showed the level of adiponectin was 
lower in gestational diabetes and adiponectin correlates negatively with insulin resistance in 
homeostasis model assessment-insulin resistance (HOMA-IR) (Altinova et al., 2007). To 
evaluate whether adiponectin is a predictive factor for gestational diabetes mellitus (GDM) 
and is appropriate as a screening test for GDM a study was done and the results 
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demonstrated that adiponectin was an independent predictor for GDM. For GDM screening, 
adiponectin was not as strong a predictor as GCT. In any case, adiponectin could be used to 
rule out pregnant women at low risk of GDM (Weerakiet et al., 2006). In a cross sectional 
study serum level of adiponectin in GDM women and impaired glucose test and normal 
pregnant women was compared. This study showed the serum adiponectin level in 
gestational diabetes was significantly lower than the impaired glucose test and control 
groups and a negative correlation between prepregnancy BMI and adiponectin 
(Soheilykhah et al., 2009). In another study, class A2 and B gestational diabetes are 
associated with a suppressed level of adiponectin (Thyfault et al., 2005 ). To investigate 
changes in serum adiponectin during pregnancy and postpartum and assess its relationship 
with insulin resistance as measured by homeostasis model assessment (HOMA-IR) a study 
was done and revealed adiponectin was lower in gestational diabetes than in control groups 
during pregnancy and a significant post reduction in adiponectin was observed in maternal 
adiponectin after delivery indicating a significant placental contribution to adiponectin 
production (Vitoratos et al., 2008). The result of the another study identified weight gain as 
the strongest factor associated with declining ǃ cell compensation for insulin resistance in 
Hispanic women at high risk for type 2 diabetes. Such effects may be mediated through at 
least two mechanisms: alteration in adipokine levels and increasing insulin resistance (Xiang 
et al., 2010). A prospective, nested case control study showed adiponectin concentration in 
early pregnancy was significantly lower in women with GDM than controls (4.4 vs. 8.1), 
approximately 73% of women with GDM, compared with 33% of controls, had adiponectin 
concentration less than 6.4µg/ml. After adjustment for confounding, women with 
adiponectin concentration in early pregnancy, less than 6.4µg/ml, experienced a 4.6-fold 
increased risk of GDM as compared with those with higher concentrations (Williams  et al., 
2004). Postpartum follow-up showed that women developing metabolic syndrome had 
significantly lower adiponectin and resistin concentration during pregnancy. Nonetheless, 
after adjustment for age, prepregnancy BMI, logistic regression analysis did not show 
independent relation between adiponectin and resistin with development of postpartum 
metabolic syndrome (Hossein-nezhad et al., 2010 ). To evaluate plasma adiponectin levels, 
insulin resistance and glucose tolerance in women with gestational diabetes mellitus and in 
normal pregnancies adiponectin measurement were performed two times as in 28–31 weeks 
of pregnancy and at 3 months after delivery. Insulin resistance was calculated by the 
homeostasis model assessment. This study demonstrated decreased adiponectin levels in 
GDM do not normalize instantaneously following the delivery. The difference is more 
apparent in adiponectin levels than in HOMA-IR (Cavit et al., 2007). Low plasma 
adiponectin concentration was associated with GDM in another study and adiponectin 
mRNA levels in adipose tissue biopsies from GDM subjects were reduced (Ranheim et al., 
2004). Concentration of adiponectin may change before the appearance of the abnormal 
glucose level during pregnancy (Xue-lian et al., 2008). To identify potential biomarkers for 
impending gestational diabetes that appear in the plasma before impaired glucose tolerance 
a prospectively study was done and the results demonstrated a significant difference in 
insulin and adiponectin concentration at 11 weeks gestation and, compared to control 
groups, women with gestational diabetes exhibited elevated plasma insulin and reduced 
plasma adiponectin at 28 weeks gestation. Bivariate logistic regression analysis showed that 
both insulin and adiponectin were associated with subsequent development of gestational 
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diabetes. Based upon this study (Georgiou et al., 2008) the predictive threshold values for 
GDM at 11 weeks are >25µU/ml insulin and <3.5µg/ml adiponectin. This study confirmed 
the another survey (Wiliams et al., 2004) that a low blood concentration of adiponectin early 
in pregnancy is associated with increased risk of subsequent GDM. 
In summary the results of case control and prospective studies demonstrated association of 
low adiponectin and GDM. 
2.2 Leptin  
2.2.1 Leptin structure  
Leptin, a protein product of the obese (ob) gene with a 16 KDA molecular weight, is made of 
167 amino acids (Hui-lan et al., 2004 ). It is a circulating hormone that is expressed plentifully 
in the adipose tissue. Leptin is also produced by non adipose tissue  including the stomach, 
intestine and the placenta in humans (Masuzaki et al., 1997) and acts on the receptors of the 
hypothalamus to decrease food intake and increase energy consumption (Zhang et al., 1994). 
Leptin is encoded by the obesity gene. It signals to the brain when there has been enough 
eating to sustain body weight. It has been exhibited that laboratory mice have a mutation on 
the ob gene which inhibits the function of leptin causing the mice to become morbidly obese. 
In addition mutation in the gene that codes  the leptin receptor causes obesity in the mice. 
Mutations in the ob gene affect expression of leptin, which in turn can cause obesity, infertility, 
and diabetes in lab mice (Zhang et al., 1997). It is hypothesized that alteration in the human ob 
gene causes some serious cases of early-onset obesity. Other less severe kinds of human 
obesity are considered not to be caused by mutation, but by changing in regulation or 
resistance to the action of leptin (Flier et al., 1995). Diminished production of leptin or fewer 
receptors may also be responsible for those who are overweight but not obese. It seems that 
the appropriate amount of leptin has to be present in the central nervous system to leptin act 
as weight lowering in human obesity (Zhang et al., 1997). 
2.2.2 Leptin action  
Homeostatic regulation of body weight depends on the capacity of the brain to sense and 
respond to changes in peripheral energy supplies. Insulin receptors were recognized in the 
brain and concentrated in the hypothalamus. These receptors have binding and signaling 
properties like peripheral insulin receptors. Leptin and insulin enter the brain and act on 
special hypothalamic neurons to prevent food intake and alter appetite. Leptin raise energy 
expenditure by regulating of neurotransmitters. (Porter et al., 2002). The evidence shows 
that insulin and leptin also act on the hypothalamus to control glucose production from the 
liver via stimulation of the autonomic nervous system. Thus, communication between 
leptin, insulin and significant hypothalamic neurons is necessary for normal energy balance 
and glucose homeostasis, deregulation of which will lead to obesity and type 2 diabetes. 
Indeed, in many forms of obesity, hypothalamic leptin and insulin resistance develops in 
which leptin and insulin are less effective in causing anorexia and decreased body weight. 
Some studies propose that leptin also has a specific effect on the regulation of whole body 
glucose homeostasis (Al-Dahhri et al., 2002; Ceddia et al., 2002). Numerous metabolic 
studies have shown a positive association between direct and indirect measures of adiposity 
with plasma leptin concentrations. Plasma leptin concentration correlated with BMI, percent 
of body fat and plasma insulin in both overweight/obese and normal weight and decreased 
after sustained weight loss (Havel et al., 1996).  
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2.2.3 Leptin and gestational diabetes 
The increased risk of GDM with increasing maternal plasma concentration of leptin is 
biologically plausible and is likely accounted for by diverse molecular and biochemical 
pathways in multiple tissue. Leptin has been shown to regulate peripheral glucose 
homeostasis through its action in skeletal muscle and its effects on hepatic gene expression 
of the gluconeogenetic enzymes and phosphoenolpyruvate carboxykinase (Rossetti et al., 
1997). In addition, leptin has been shown to directly modulate glucose handling in skeletal 
muscle by promoting fatty acid oxidation. Investigators have postulated that leptin induced 
insulin resistance may be secondary to glucose flux via the hexosamine pathway (Mueller et 
al., 1998). Although the pathophysiology of hyperleptinemia in GDM is unknown, it is clear 
that leptin has numerous actions on target tissues and is involved in regulation on several 
endocrine pathways. Although the biologic action of leptin primarily mediated through 
interactions with receptors expressed in the hypothalamus, leptin receptors are widely 
distributed across other tissues including the lungs, liver, kidney, pancreas, heart and the 
placenta (Chen et al., 1999; Hoggard et al., 1997; Kieffer et al., 1996; Schulz et al., 2000). This 
wide distribution of leptin receptors portends the peptide diverse influence on 
neuroendocrine, cardiovascular and reproductive functions. Leptin is correlated with a 
series of endocrine parameters including insulin, insulin-like growth factors, hemoglobin 
A1c and sex hormone-binding globulin 
In pregnant women with changes in maternal fat stores and glucose metabolism, leptin 
increases (Schubring et al., 2000). Maternal leptin concentration increases 2 to 3 times above 
the non-pregnant concentration with the peak around 28 weeks of gestation (Schubring et 
al., 2000). The serum leptin level relates to body weight, body mass index, fat accumulation 
of the pregnant woman, fetal growth and development and fetal fat deposits. In recent 
years, it was considered that leptin is associated in pregnancy-induced hypertension 
syndrome, fetal intrauterine growth retardation and gestational diabetes. Increasing 
maternal plasma leptin levels may result from an upregulation of adipocyte leptin synthesis 
in the presence of increasing insulin resistance and hyperinsulinemia in the second half of 
pregnancy (Laivuori et al., 2000; Rossetti et al., 1997). Investigators have shown that leptin 
directly affects whole body insulin sensitivity through regulating the efficiency of insulin-
mediated glucose metabolism by skeletal muscle (Cohen et al., 1996) and by hepatic 
regulation of gluconeogenesis (Rossetti et al., 1997). Some evidence suggests that leptin has 
an acute inhibitory effect on secretion of insulin (Ceddia et al., 2002). Large epidemiological 
studies have shown that plasma leptin concentrations were positively associated with 
insulin resistance in men and non-pregnant women (Donahue et al., 1999).  
Available data suggest a complex relation between leptin and glucose homeostasis in 
humans. Two teams of investigators have studied maternal leptin concentrations in GDM 
women and the related published results are conflicting. On the other hand, the available 
data do not explain whether the alterations in leptin concentrations are the cause or result of 
the metabolic disturbances, such as hyperglycemia, that are essential to GDM. In addition, 
the severity of any possible association of GDM risk with different concentrations of leptin 
was not assessed in either study (Festa et al., 1999; Kautzky-Willer et al., 2001). In a case-
control study reported that maternal third-trimester plasma leptin concentrations were 
higher in GDM women compared with the control group (24.9 versus 18.2 ng/mL; P=0.001) 
(Kautzky-Willer et al., 2001). Such a relation was also found in other study. (Vitoratus et al., 
2000)  Hyperleptinemia, independent of maternal adiposity, in early pregnancy appears to 
be predictive of an increased risk of GDM later in pregnancy. After adjusting for maternal 
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prepregnancy adiposity and other confounders, women with leptin concentrations of 
31ng/ml or higher experienced a 4.7-fold increased risk of GDM as compared with women 
who had concentrations of 14.3ng/ml or lower. Each 10-ng/ml increase in the leptin 
concentration was associated with a 20% increase in GDM risk (Qiu et al., 2004). Serum 
leptin level is correlated with glucose tolerance during pregnancy (Liu et al., 2003). In a case-
control study, at 28 weeks of gestation, fasting serum concentration of leptin, insulin and 
homeostatic model assessment index were measured in three groups, GDM, IGT, and 
normal control, and compared them with each other. This study demonstrated that the 
serum leptin level was significantly higher in women with GDM than in the two other 
groups ( p = 0.03). In women with GDM and IGT, leptin was significantly positively related 
with insulin and homeostatic model assessment index (r = 0.221, p = 0.03) and (r = 0.246, p = 
0.03), respectively. (Soheilykhah et al., 2011) 
In a case-control study, noted that maternal third trimester leptin concentrations were 
significantly lower in GDM cases as compared with controls after adjusting for possible 
confounding factors such as BMI and insulin concentrations (Festa et al., 1999). 
Concentration of leptin increased before the appearance of the abnormal glucose level 
during pregnancy (Xue-lian et al., 2008). Some studies evaluated the relationship between 
leptin concentration and insulin resistance. Leptin concentration was positively associated 
with insulin level and HOMA index (Maghbooli et al., 2007). A positive and significant 
correlation between the maternal leptin and fasting insulin levels (Liu et al., 2003) and also 
has shown that leptin predicts the development of GDM independent of maternal BMI and 
other risk factors. The findings of Kautzky-Willer et al are generally consistent with the 
Different reports. (Kautzky-Willer et al., 2001 ,Lappas et al., 2005 Qiu et al., 2004). 
Several possible explanations are suggested for the disparities in the existing studies. The 
study design and the confounding factors such as the time of blood sampling (whether 
blood samples were collected before, after, or during labor) and maternal factors, including 
whether women were treated with medication or diet before blood was collected for leptin 
determination might account for differences. Moreover, variations in population 
characteristics and status of glycemic control could also account for some of the observed 
differences in the study results. 
In summary, the results of different studies from experimental, clinical, and epidemiological 
investigations suggest that leptin is an important mediator of glucose homeostasis in 
pregnancy (Qiu et al., 2004) and measurement of leptin alone, or combined with the 
assessment of other risk factors, may help identify women at risk of developing GDM. 
2.3 Resistin 
2.3.1 Resistin structure  
Insulin resistance is strongly associated with obesity, but even among obese subjects insulin 
sensitivity is different. Recently, a new adipocyte hormone, resistin, was identified, shown 
to decrease insulin-mediated glucose uptake, and shown to be increased in obese mice 
Resistin, also known as adipose tissue-specific secretory factor , is a cystein-rich protein that 
in humans is encoded by the RETN gene (Wang et al., 2002). Resistin was discovered to be 
produced and released from adipose tissue to provide endocrine functions likely involved 
in insulin resistance. This thought initially developed from studies exhibiting that serum 
resistin levels increase with obesity in several species (humans, rats, and mice) . (Yamauchi 
et al., 2003; Gabriely et al., 2002; Steppan et al., 2001). Resistin is also produced by several 
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other tissues, including the hypothalamus, pituitary and adrenal glands, pancreas, 
gastrointestinal tract, myocytes, spleen and white blood cells  
The role of resistin in obesity and insulin resistance in humans is controversial.  
2.3.2 Resistin action 
Resistin causes insulin resistance and glucose intolerance in mice. Serum resistin levels will 
rise with increased adiposity, particularly central obesity (Degawa-Yamauchi et al., 2003; 
Vendrell et al., 2004). Conversely, serum resistin levels decrease with lowering adiposity 
following medical treatment (Valsamakis et al., 2004). The level of tissue resistin is 
decreased by insulin, cytokines such as tumour necrosis factor, ǂ endothelin-1 and increased 
by growth and gonadal hormones, hyperglycaemia, interleukin-6 and lipopolysaccharide 
(Adeghate, 2004). Animal study exhibited that resistin gene expression and protein levels 
are regulated  in parallel with glucose and insulin during fasting and feeding Many 
researchers have shown positive correlations between resistin levels and insulin 
resistance.Thus resistin has been suggested to link obesity with type 2 diabetes (Hirosumi et 
al., 2002; Rajala et al., 2004; Silha et al., 2003; Smith et al., 2003). This discovery is further 
confirmed by studies which verified a direct correlation between resistin levels and subjects 
with type 2DM (Asensio et al., 2004; Fujinami et al., 2004; McTernan et al., 2003; Steppan et 
al., 2001). With the finding that resistin was at least in part a cause of the insulin resistance 
and T2DM, medications which specifically lead to decreased serum resistin in T2DM 
subjects were developed(Tjokroprawiro, 2006). The level of circulating resistin is decreased 
by the anti-diabetic drug  such as rosiglitazone and increased by obesity. Administration of 
the anti resistin antibody decreases blood sugar and improve insulin action in mice with diet 
induced obesity. Treatment of normal mice with recombinant resistin impairs glucose 
tolerance and decreases insulin action. Insulin stimulated glucose uptake by adipocyte is 
increased by neutralization of resistin and is reduced by resistin treatment (Steppan et al., 
2001). Because resistin is identical to a protein which had a role in allergic pulmonary 
infiltration, the effect of resistin in inflammation was studied and these researches 
demonstrated association of resistin with other physiological systems such as inflammation 
and energy homeostasis (Adeghate, 2004; Stumvoll & Häring, 2002; Vendrell et al., 2004). 
2.3.3 Resistin and gestational diabetes  
Resistin is expressed in human placenta and has been supposed to play a role in regulating 
energy metabolism in pregnancy. Resistin protein expression in placental tissue was much 
higher than that in subcutaneous adipose tissue in normal human abdomen, pregnant 
abdomen and thigh. It was indicated that resistin protein can be secreted from human 
placental tissue. Resistin might be one of the factors that lead to pregnant physiological 
insulin resistance and GDM (Yongming et al., 2006).Resistin is secreted by the placenta 
during human pregnancy (Sagawa et al., 2002) Serum resistin levels are not different among 
non-pregnant women and women in the first and second trimesters of pregnancy .Serum 
resistin  increases by the third trimester (Chen et al., 2005). Resistin is detectable at 20 weeks 
of gestation. In newborns, resistin concentrations were two to three-fold higher than those 
reported in adults regardless of sex, birth weight, pattern of growth or metabolic state of the 
mother (Yongming et al., 2006). Resistin gene expression is found in placental tissues during 
pregnancy (Yura et al., 2003) and it has been supposed that it could be involved in the 
pathogenesis of the insulin resistance state found in the second half of pregnancy and in the 
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development of gestational diabetes. Resistin levels were significantly higher in normal 
pregnant women than in nonpregnant controls and showed a negative correlation with 
gestational age. Resistin was detected in the umbilical venous blood in fetus from 20 to 41 
weeks of gestation. Detection of high levels of resistin in cord blood during gestation is 
consistent with a regulatory action of these adipokines on tissue differentiation and foetal 
growth (Cortelazzi et al., 2007). Recent reports have measured the level of resistin during 
pregnancies complicated by gestational diabetes with inconsistent results (Cortelazzi et al., 
2007, Chen et al., 2007). The result of a study showed resistin level in gestational diabetes 
was lower than normal pregnancy(Megia et al.,2008)This result inconsistent with other 
study that demonstrated  serum resistin concentration was significantly higher in women 
with GDM than in controls before delivery and the  serum levels of resistin significantly 
decreased after delivery in both the GDM group and controls.The serum level of resistin 
was different on days 1 and 3 but not by day 5 after delivery (Chen et al.,2007). The serum 
resistin levels were higher in the 1st, 2nd and 3rd trimesters of pregnancy and higher in 
GDM than in control groups and hyperresistinemia may also be associated with the 
pregnancy-induced insulin resistance (Palik et al., 2007). The discrepancy of these findings is 
unclear, but may be related to different populations of the studies, the type of study or the 
time of sampling during pregnancy. 
3. Inflammatory mediators (C-reactive protein) 
3.1 C-reactive structure and actions 
C-reactive protein (CRP) is a sensitive marker of systemic infection and is widely used in 
clinical settings (Kushner I& Rzewnicki, 1994). CRP was first detected in 1930 by Tillet and 
Frances (Tillett & Francis, 1930), who identified a substance that formed a precipitate when 
combined with polysaccharide C of streptococcus pneumonia in the sera of patients acutely 
infected with pneumococcal pneumonia. Subsequently, it was found that this reaction was 
not unique to pneumococcal pneumonia but could be found with a variety of the other acute 
infections. This was early evidence of the body’s chemical response to inflammatory states 
and led to characterization of other so called acute phase proteins (Abernathy & Avery, 
1941). CRP is normally present in low levels in serum but increase rapidly and dramatically 
in response to a variety of infectious or inflammatory conditions (Ballou & Kushner, 1992). 
Since its discovery, CRP has been studied as a screening device for occult inflammation, as a 
marker of disease activity and as a diagnostic tool (Pepys, 1981). Recently, more rapid and 
accurate methods of quantifying CRP have lead to a new interest in its value in clinical 
medicine (Palosuo et al., 1986) although low-grade inflammatory states not originated from 
infections and atherosclerosis have also been associated with an increase in CRP levels. For 
instance, obesity is linked to chronic subclinical inflammation as manifested by mild increases 
in CRP cytokines and adipocytokines and is the principal risk factor for type 2 diabetes. In 
addition, patients with increases in CRP are at risk of myocardial infarction and peripheral 
arterial disease (Engström et al., 2003; Ford, 1999; Ridker et al., 2000; Tracy et al., 1997; Yudkin 
et al., 1999). Elevated serum concentration of acute-phase proteins, exhibiting chronic 
subclinical inflammation, has been associated with insulin resistance syndrome in men and 
non-pregnant women (Festa et al., 2000; Han et al., 2002; Pradhan et al., 2002; Ridker et al., 
2003). The molecular basis for the association between the inflammation and diabetes related 
to the action of cytokines such as interlukin-6 and tumor necrosis factor (TNF)-ǂ which lead to 
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insulin resistance and stimulate the acute phase inflammatory response (Fernandez-Real et al., 
2001; Kern et al., 2001; Mohamed-Ali et al., 1998; Vozarova et al., 2001).  
3.2 C-reactive protein and GDM 
Some evidence supports the theory that chronic inflammation might be a risk factor for 
developing type 2 diabetes (Freeman et al., 2002; Pradhan et al., 2001; Taniguchi et al., 2002; 
Thorand et al., 2003). Inflammation may have a role in the pathogenesis of diabetes, 
suggesting that inflammatory markers may identify patients at risk of diabetes. The issue 
was investigated in a subset of women (1584 who developed diabetes and 2193 who were 
normal after 6 years. Women with diabetes had higher median baseline level of interleukin-
6 (IL6), high sensitivity CRP and tumor necrosis factor alpha receptor 2 compared with 
control.Two markers (IL6 and CRP) were significantly associated with diabetes risk in all 
ethnic groups (Liu et al., 2007).Similar results were obtained in the women's health study 
(Pradhan et al., 2001) and the nurse health study (Hu et al., 2004). In a population –based 
study in Mexico City, serum CRP was a predictor of the metabolic syndrome and type 2 
diabetes in women but not in men (Han et al., 2002). Among middle aged men in Germany 
those with a serum CRP in the highest quartile ≥2.91ng/ml had an increased risk of type 2 
diabetes compared with men in the lowest quartile (≤0.67ng/ml) (RR 2.7,95%CI1.4-5.2) 
(Thorand et al., 2003). Epidemiological studies have shown that CRP predicts incident type 2 
diabetes and increased cardiovascular disease. In healthy middle-aged women, or young 
men, CRP levels were associated with a three–fourfold increased risk of developing diabetes 
(Buchanan,2001; kjos &Buchanan,1999). 
Very limited attention has been given to the role of inflammation in the etiology of gestational 
diabetes a condition that is biochemically and epidemiologically similar to type 2 diabetes 
(kjos & Buchanan,1999).The second and third trimesters of pregnancy represent a 
physiological type of insulin resistance (Kautzky-Willer  et  al., 1997). Insulin resistance is 
associated with dysfunction of endothelial and inflammation as well as increase production of 
cytokines by adipose tissue(Baalletshofer et al.,2000). Limited available data suggest that pro-
inflammatory cytokines may be predictive of GDM(Winkler et al., 2002; Kirwan et al., 2002). 
Some studies have measured CRP at various gestational ages in pregnant women and found 
inconsistent results regarding the association between inflammatory markers and the 
incidence of GDM and the interdependence with the degree of adiposity (Retnakaran et al., 
2003; Wolf et al., 2003,2004). The interpretation of the results was influenced by coexistence 
of hypertension, preeclampsia, and different race groups or small sample size in some 
studies. The result of a study demonstrated women with GDM had significantly higher CRP 
serum levels than normal pregnant women at 37-38 weeks of gestation but at the time of 
OGTT (24-28 weeks of pregnancy) there was not any significant difference between the two 
groups (Leipold et al. , 2005 ). This report is inconsistent with the findings of the 
Massachusetts General Hospital obstetric maternal report, where increased CRP 
concentration was shown in the first trimester (10 weeks of gestation) and the association 
between GDM and CRP depended primarily on coexisting obesity (Wolf et al., 2004). The 
result of another study demonstrated that CRP concentration is not affected by GDM until 
the end of the second trimester of pregnancy (Retnakaran et al., 2003). In the third trimester, 
however, these results suggest an up-regulation of inflammatory markers by GDM resulting 
in elevation of CRP concentration at the end of pregnancy in women with GDM. In a 
prospective nested case control study Wolf et al found that CRP concentration in the first 
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trimester predicted the development of GDM in the pregnancy. In this study risk of 
developing GDM among women in the highest CRP tertile compared with the lowest tertile 
was 3.2 (95% CI 1.2-8.8), after adjusting for age, race, smoking, parity, blood pressure and 
gestational age at CRP sampling. The risk of developing GDM among women in the highest 
compared with the lowest tertile was 3.6 (95%CI 1.2-11.4), when BMI was included in the 
model; however, the association between increased CRP and GDM was reduced (odds ratio 
for the highest compared with the lowest tertile 1.5 (95% CI 0.4-5.51). Therefore, this 
association is mediated in part by increasing BMI (Wolf et al., 2003) and pregestational 
obesity as the most prominent risk factors of GDM (Wolf et al., 2003). 
Another prospective study was done to examine the association between CRP and GDM 
risk. Women were recruited before 16 weeks gestation and were followed until delivery. 
This study demonstrated elevated CRP was associated with GDM risk. After adjustment of 
maternal prepregnancy BMI, family history of diabetes and nulliparity, women with CRP in 
the highest tertile experienced a 3.5-fold increased risk of GDM (95% CI 1.2-9.8) as compared 
with those in the lowest tertile. The association between CRP and GDM was evident when 
analyses were restricted to lean women (BMI<25kg/m2). Lean women with CRP ≥5.3mg/l 
had a 3.7-fold increased risk of GDM (95%CI 1.6-8.7) as compared with women with CRP < 
5.3mg/l. This study concluded systemic inflammation is associated with an increased risk of 
GDM and this association is independent of maternal prepregnancy adiposity (Qiu et al., 
2004). Serum CRP in gestational diabetes and pregnant control women was evaluated and 
showed CRP was positively related with fructose amine hemoglobin A1c, triglyceride and 
BMI. This study concluded CRP plays a role in pathogenesis of GDM (Li et al., 2010). The 
association of sex hormone-binding globulin, high sensitive C-reactive protein and fasting 
glucose and insulin in the late first trimester and early second trimester of pregnancy with 
the diagnosis of gestational diabetes were also evaluated. In this study sex hormone-binding 
globulin was lower and high-sensitive CRP was higher among women who subsequently 
developed gestational diabetes. Multivariate analysis suggested that sex hormone-binding 
globulin measurement was the best predictor of GDM (Smirnakis et al., 2007). A 180 healthy 
pregnant women undergoing oral glucose tolerance testing in the late second or early third 
trimester were evaluated . Based on OGTT and prepregnancy BMI, participants were 
divided to 4 groups:  (1) normal OGTT and BMI<25kg/m2; (2) normal OGTT and BMI >25; 
(3) impaired glucose tolerance, and (4) GDM. This study showed CRP level was higher in 
overweight women with normal OGTT, followed by GDM, impaired OGTT groups and lean 
normal GTT. This study demonstrated that maternal CRP are not related to GDM, but rather 
correlate significantly with prepregnancy obesity (Rentakaran et al., 2003).  
4. Vitamin D 
4.1 Vitamin D structure and actions  
Vitamin D, or calciferol, is a group of lipid soluble substance with a four-ringed cholesterol 
backbone. Human obtained Vitamin D from exposure to  Sunlight, their diet and from 
dietary supplement. Ultraviolet light convert provitamin D to vitamin D3 (cholecalciferol) in 
the skin and afterwards Vitamin D3 was bounded  by vitamin D binding proteins (DBP) and 
transported via blood to target organs for metabolism and activity. Vitamin D hydroxylate 
to form 25-hydroxy-vitamin-D (25OHD) in the liver. Hydroxylation of 25-hydroxy-vitamin-
D to 1, 25-dihydroxy-vitamin D occurs in the mitochondria of the proximal tubules of the 
kidney.This form of vitamin D (1,25(OH)2-vitamin D) is the physiologically active form. The 
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renal production of 1,25-dihydroxy-vitamin D is regulated by plasma parathyroid hormone 
and serum calcium and phosphorus levels.Vitamin D increases calcium and phosphorus 
absorption from the gut and reabsorption from the kidneys and increases plasma 
concentration of these elements. As such, the main effect of vitamin D is maintenance of 
mineral homeostasis and regulation of bone remodeling (Holick et al., 2006) . 
Vitamin D deficiency is defined when the level of 25- Hydroxyvitamin D is less than 20 
ng/ml(50 nmol/l). Level of 25-29 ng/ml can be considered to indicate a relative 
insufficiency of vitamin D and a level of 30 ng/ml or more indicate sufficient vitamin 
D.Vitamin D intoxication is observed when serum level of 25-hydroxyvitamin D are greater 
than 150 ng/ml( Dawson et al.,2005). 
Vitamin D deficiency or resistance is caused by different mechanisms including reduced of 
vitamin D access due to insufficient dietary vitamin D, fat malabsorptive disorders, and/or 
lack of photoisomerization, Impaired hydroxylation of  vitamin D by the liver and kidney to 
produce 25-OH vitamin and 1,25(OH)2-vitamin D respectively and end organ insensitivity 
to vitamin D metabolites. 
4.2 Vitamin D deficiency and diabetes 
Some human and animal studies have shown a relationship between diabetes type 1and 
vitamin D deficiency .Vitamin D deficiency make  predispose subjects to type 1 and type 2 
diabetes, and receptors for its activated form 1, 25-dihydroxy-vitamin D have been 
recognized in beta cells and immune cells. Vitamin D deficiency impairs insulin synthesis 
and secretion in humans and animal models of diabetes and some investigations suggested 
that vitamin D deficiency  has a role in the development of type 2 diabetes. Epidemiological 
studies recommended a link between vitamin D deficiency in early life and the  
subsequently onset of type 1 diabetes. In some populations, type 1 diabetes is associated 
with certain polymorphisms within the vitamin D receptor gene. In studies in non obese 
diabetic mice, pharmacological doses of 1alpha,25-dihydroxyvitamin D3, or its structural 
analogues, have been shown to delay the onset of diabetes, mainly through immune 
modulation. Vitamin D deficiency may, therefore, be included in the pathogenesis of both 
types of diabetes.(Luong et al., 2005; Mathieu et al., 2005). Vitamin D supplementation could 
improve or prevent diabetes   This effect may be due to immunomodulatory action of 
vitamin D. (Stene et al., 2000; Eva , 1999). 
There was less data about the association between vitamin D and type 2 diabetes. Some 
evidences show the role of vitamin D in insulin secretion, for example the presence of 
vitamin D receptors in ǃ cells and the vitamin D-binding proteins in pancreatic tissue and 
the association between specific allelic variations in the vitamin D receptor and vitamin D-
binding protein genes with glucose tolerance and insulin secretion have further supported 
this hypothesis. The mechanism of action of vitamin D in type 2 diabetes is thought to be 
mediated not only through regulation of plasma calcium levels, which regulate insulin 
synthesis and secretion, but also through a direct action on pancreatic beta-cell 
function(Palomer et al.,2008).Vitamin D deficiency decreases insulin secretion without 
changing in glucagon secretion. The effects of a vitamin D deficiency on insulin and 
glucagon secretion was obtained in isolated perfused rat pancreas by radioimmunoassay of 
the secreted proteins. Throughout a 30-minute times of perfusion with glucose and arginine, 
pancreases from vitamin D-deficient rats showed a 48 percent reduction in insulin secretion 
compared to that for pancreases from vitamin D-deficient rats that had been resupplied with 
vitamin D. Vitamin D status had no effect on pancreatic glucagon secretion. This result, 
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along with the previously demonstrated presence in the pancreas of a vitamin D-dependent 
calcium-binding protein and cytosol receptor for the hormonal form of vitamin D, 1,25-
dihydroxyvitamin D3, indicates an important role for vitamin D in the endocrine 
functioning of the pancreas. The data demonstrated a positive correlation of 25(OH)D 
concentration with insulin sensitivity and a negative effect of hypovitaminosis D on 
function of ß cell. Subjects with hypovitaminosis D are at higher risk of insulin resistance 
and the metabolic syndrome.Vitamin D repletion in early stages of experimental dietary 
vitamin D deficiency and in vitamin D deficiency subjects improves glucose intolerance and 
increases insulin secretion. Some studies demonstrated that vitamin D supplementation 
increased insulin secretion in response to an oral glucose load in patients with type 2 
diabetes but not in patients with established type 2 diabetes (Chiu et al., 2004; Inomata et al., 
1986; Orwoll et al., 1994; Gedik & Akalin, 1986). Some evidence indicates that vitamin D 
increases  insulin secretion from ǃ cells by increasing intracellular calcium concentration 
through nonselective voltage-dependent calcium channels. The main effect of vitamin D on 
insulin secretion is acquired from conversion of proinsulin to insulin. Calcium is principal 
not only for insulin exocytosis but also for cell glycolysis ( Boucher, 1998). Vitamin D also 
activates protein biosynthesis in pancreatic islets. Vitamin D deficiency reduces insulin 
secretion and action. Variation in the vitamin D receptor  or vitamin D-binding protein 
causes glucose intolerance. 
Vitamin D increases cellular glucose absorption either directly or by increasing insulin 
sensitivity. Vitamin D may directly or indirectly regulate ǃ cell function and secretion by 
binding 1,25 dihydroxy vitamin D to ǃ cell vitamin D receptors and controlling the balance 
between the extracellular and intracellular ǃ cell calcium pools (Norman et al ., 1980). 
Vitamin D can promote insulin sensitivity by stimulating the expression of insulin receptors 
and enhancing insulin responsiveness for glucose transport. It also regulates extracellular 
calcium and thus establishes normal calcium inflow through cell membranes and an 
adequate intracellular cytosolic calcium pool, which is necessary for the insulin-mediated 
intracellular process in insulin responsive tissues (Draznin et al.,1988). 
4.3 Vitamin D deficiency and gestational diabetes 
Data about vitamin D as a risk factor for GDM is spare. Pregnant women with diabetes are 
known to be more vitamin D deficient compared with normal pregnant women (Bikle, 
1992). Intravenous administration of vitamin D to pregnant women with gestational 
diabetes transiently decreases fasting glucose; however, the level of insulin also decreases 
(Rudnicki & Molsted-Pedersen, 1997). Vitamin D deficiency was associated with a 2.66-fold 
increase in GDM risk and each 5 ng/ml decrease in 25-hydroxy D concentrations was 
related to a 1.29-fold increase in GDM risk (Zhang et al., 2008). Another study demonstrated 
that the serum concentration of vitamin D during 24-28 weeks of pregnancy in gestational 
diabetes was lower than normal groups (Maghbooli et al., 2007; Soheilykhah et al., 
2009).Women with GDM had a 2.66 fold increased risk of vitamin D deficiency (25-hydroxy 
D<15ng/ml) compared with control group(Soheilykhah et al.,2009). Maternal 
hypovitaminosis was reported in diabetic pregnancies in Spain and fasting glycaemia 
decreased with vitamin D supplementation (Farrant et al., 2008). Vitamin D, insulin and 
proinsulin were measured at 30 weeks gestation in another study . This study demonstrated 
that vitamin D insufficiency is common in mothers but is not associated with gestational 
diabetes. There was no association between maternal 25(OH)D and gestational diabetes.In 
this study mothers with hypovitaminosis D, higher 25(OH)D concentrations were associated 
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with lower 30-min glucose concentrations and higher fasting proinsulin concentrations 
(Farrant et al., 2009). Clifton-Bligh et al. showed mean serum 25(OH)D concentration  in 
pregnant women was negatively correlated with fasting plasma glucose, fasting insulin and 
insulin resistance as calculated by homeostasis model assessment. The association between 
fasting glucose and log-transformed 25OHD concentration was of borderline significance 
after accounting for ethnicity, age and body mass index in multivariate analyses. The odds 
ratio of gestational diabetes in women with 25OHD < 50 nmol/L did not reach statistical 
significance (1.92, 95% confidence interval 0.89-4.17) (Clifton-Bligh et al., 2008). 
In another study total prevalence of vitamin D deficiency (<25 nmol/L) was 70.6% in pregnant 
women. Prevalence of severe vitamin D deficiency (<12.5) in GDM patients was higher than in 
normoglycaemic pregnancies. These results show that a positive correlation of 25(OH) vitamin 
D concentrations with insulin sensitivity and vitamin D deficiency could be a confirmative 
sign of insulin resistance (Maghbooli et al., 2007). Several studies suggest that vitamin D 
supplementation in children reduces the risk of type 1 diabetes. Increasing vitamin D intake 
during pregnancy reduces the development of islet autoantibodies in offspring (Chiu et al., 
2003). In Finland, 10,366 children who were given 2000 IU of vitamin D3 per day during 
their first year of life were followed for 31 years. The risk of type 1 diabetes was reduced by 
approximately 80% (relative risk, 0.22; 95% CI, 0.05 to 0.89) ( Hypponen et al., 2001). Among 
children with vitamin D deficiency, the risk was increased by approximately 200% (relative 
risk, 3.0; 95% CI, 1.0 to 9.0). In another study, vitamin D deficiency increased insulin 
resistance, decreased insulin production, and was associated with the metabolic syndrome 
(Chiu et al., 2004). Another study demonstrated that a combined daily intake of 1200 mg of 
calcium and 800 IU of vitamin D lowered the risk of type 2 diabetes by 33% (relative risk, 
0.67; 95% CI, 0.49 to 0.90) as compared with a daily intake of less than 600 mg of calcium and 
less than 400 IU of vitamin D (Pittas et al., 2006). 4000 IU vitamin D  was administrated for 6 
months to women with vitamin D less than 50 nm/Land  median serum 25(OH)D3 
increased significantly and insulin resistance and fasting insulin decreased (Von Hurst et al., 
2010).In summary the result of different studies show high prevalence of vitamin D 
deficiency in pregnant women and most of these findings demonstrated the relationship 
between vitamin D status and glucose tolerance  in pregnancy. 
5. Conclusion 
Early diagnosis of gestational diabetes prevents maternal and fetal complications . Recently 
a number of studies illustrated association of various biomarkers with subsequent 
development of GDM . These metabolic mediators are known to be  produced in  the 
intrauterine environment . Some studies demonstrated that decreased level of adiponectin 
and increased level of leptin and resistin preceded the onset of diabetes in pregnancy.  
Some investigations  also have been shown  association between C-reactive protein and risk 
of GDM. Some researches exhibited maternal vitamin D concentration inversely related to 
fasting glucose and insulin concentration and vitamin D deficiency was associated with 
increasing risk of GDM. 
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